^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    23h
    TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Antalya Training and Research Hospital
    New trial • Real-world evidence • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    1d
    The interaction of PD-1/PD-L1 and its inhibition by anti-PD-L1 antibody at the single-molecule level. (PubMed, FEBS Lett)
    In this work, the two complete complex structures in the protein native state of PD-1 with PD-L1, and the anti-PD-L1 antibody atezolizumab were investigated by atomic force microscopy (AFM) single-molecule force spectroscopy and predicted by AlphaFold modeling...Impact statement Our research developed a novel and close-to-native physiological platform to evaluate protein interactions from structural, mechanical, and kinetic perspectives at the single-molecule level. This could be applied in the design of more effective checkpoint inhibitory molecules and provides relevant methodologies for evaluating single-molecule macromolecular interactions.
    Journal
    |
    PD-1 (Programmed cell death 1)
    |
    Tecentriq (atezolizumab)
    2d
    A-Brave: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (clinicaltrials.gov)
    P3, N=474, Completed, Istituto Oncologico Veneto IRCCS | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Bavencio (avelumab)
    2d
    CTX-8371-001: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=73, Recruiting, Compass Therapeutics | N=55 --> 73 | Trial completion date: Apr 2026 --> May 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    3d
    PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. (PubMed, J Hematol Oncol)
    PACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR expression
    |
    Imfinzi (durvalumab)
    3d
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    4d
    A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, AstraZeneca | Trial completion date: Oct 2025 --> Mar 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    4d
    TAZMAN: Study of AZD2811 + Durvalumab in ES-SCLC (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV • barasertib-HQPA (AZD2811)
    4d
    Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab (clinicaltrials.gov)
    P2, N=15, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    4d
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=254, Active, not recruiting, Shanghai Henlius Biotech
    New P1 trial
    4d
    Molecularly guided precision therapy in metastatic adamantinoma: a case report. (PubMed, Per Med)
    She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
    Journal • PARP Biomarker • PD(L)-1 Biomarker
    |
    XRCC2 (X-Ray Repair Cross Complementing 2)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab)
    4d
    Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer. (PubMed, Ann Med)
    The GEMSTONE-303 trial demonstrated that sugemalimab combined with capecitabine and oxaliplatin (CAPOX) improved survival benefit in patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) and a programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥5. It is essential to adopt a combination of targeted patient selection, price negotiation, and broader PAP access to bring the ICER below the WTP threshold. These findings inform reimbursement negotiations and highlight the need for stratified pricing strategies to optimize accessibility in economically diverse populations.
    Journal • HEOR • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine • oxaliplatin • Cejemly (sugemalimab)